Core Viewpoint - The approval of the recombinant type I α1 collagen and sodium hyaluronate composite solution by the National Medical Products Administration of China marks a significant milestone for the company, enhancing its position in the aesthetic medicine market [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Shaanxi Juzhi Biotechnology Co., Ltd., received the Medical Device Registration Certificate for the composite solution, which is the first of its kind globally for improving cheek smoothness [1] - The product is primarily composed of recombinant collagen and sodium hyaluronate, intended for injection into the dermis [1] Group 2: Market Impact - The stock price of the company increased by 5.38%, reaching HKD 37.84, with a trading volume of HKD 16.51 million following the announcement [1] - CICC expressed optimism regarding the product's approval, which is expected to further expand the company's aesthetic product matrix and validate its leading technological research and development capabilities [1] Group 3: Future Strategy - The company plans to steadily advance the product's market launch and promotion through a diversified product portfolio, comprehensive channel network, and refined brand operations [1] - The aim is to provide differentiated solutions and continuously strengthen its leading market position in the health and beauty sector [1]
港股异动 | 巨子生物(02367)涨超5% 注射用重组胶原蛋白和透明质酸钠复合溶液获批